Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 7/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133286 | 1.00 | TASP1 (0.43) | TASP1BACE1GNPATBMP1CTSD | |
| SCHEMBL23133168 | 1.00 | TASP1 (0.43) | TASP1BACE1GNPATBMP1CTSD | |
| SCHEMBL29946126 | 0.88 | TASP1 (0.45) | TASP1BACE1GNPATBMP1CTSD | |
| SCHEMBL20257262 | 0.87 | FNTA (0.42) | TASP1BMP1CASP1 | |
| SCHEMBL29664764 | 0.84 | TASP1 (0.56) | TASP1BACE1GNPATBMP1BACE2 | |
| SCHEMBL12149975 | 0.83 | BACE1 (0.47) | BACE1GNPATBMP1CTSDBACE2 | |
| SCHEMBL24616790 | 0.83 | TASP1 (0.48) | TASP1GNPATBMP1PTPN1SIRT5 | |
| SCHEMBL29946268 | 0.80 | TASP1 (0.51) | TASP1BACE1GNPATBMP1BACE2 | |
| SCHEMBL31107824 | 0.79 | GNPAT (0.51) | BACE1GNPATBACE2 | |
| SCHEMBL30464991 | 0.79 | GNPAT (0.51) | BACE1GNPATBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| JP-2011508221-A | — | — | 2011-03-10 | — | — | JP | claimed |
| US-20100255120-A1 | COMPOSITIONS FOR FORMING IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. | 2010-10-07 | — | — | US | claimed |
| EP-2225388-A1 | COMPOSITIONS FOR FORMING IMMOBIIZED BIOLOGICAL LAYERS FOR SENSING | Abbott Point Of Care, Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009082699-A1 | COMPOSITIONS FOR FORMING IMMOBIIZED BIOLOGICAL LAYERS FOR SENSING | I-STAT CORPORATION (US) | 2009-07-02 | — | — | WO | claimed |
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-3312273-B1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | UNIV TOKYO SCIENCE FOUND (JP) | 2024-07-24 | — | — | EP | disclosed |
| US-20120270756-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8241697-B2 | Formation of immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100255120-A1 | COMPOSITIONS FOR FORMING IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2235513-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | Abbott Point Of Care, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-2225388-A1 | COMPOSITIONS FOR FORMING IMMOBIIZED BIOLOGICAL LAYERS FOR SENSING | Abbott Point Of Care, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009105145-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | I-STAT CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009082699-A1 | COMPOSITIONS FOR FORMING IMMOBIIZED BIOLOGICAL LAYERS FOR SENSING | I-STAT CORPORATION (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090159442-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885GNPAT 3426/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885GNPAT 3426/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885GNPAT 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.